ADRs Close Higher; Phoenix New Media Ltd. Cl A Climbs 38%
BioLineRx Stock Jumps 14% on St. Jude Clinical Trial for Mitoxafortide
Express News | BioLineRx Announces Multi-Center Phase 1 Trial Sponsored By St. Jude Children's Research Hospital To Evaluate Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications In Sickle Cell Disease
Earnings Call Summary | BioLine Rx(BLRX.US) Q1 2024 Earnings Conference
BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript
Express News | BioLineRx Shares Are Trading Higher. The Company Reported Q1 Financial Results
BioLine Rx | 6-K: Report of foreign private issuer (related to financial reporting)
Express News | BioLineRx Says Cash, Cash Equivalents, And Short-Term Bank Deposits Of $28.2M Will Be Sufficient To Fund Operations, As Currently Planned, Into 2025
BioLine RX 1Q Rev $6.86M >BLRX
Express News | BioLine Rx Q1 2024 GAAP EPS $(0.00) May Not Be Comparable To $(0.29) Estimate, Sales $6.855M May Not Be Comparable To $340.000K Estimate
Express News | BioLineRx Discloses Abstract On Pilot Study Data From Phase 2 Combination Clinical Trial Evaluating Motixafortide In First-Line Pancreatic Cancer At American Society of Clinical Oncology 2024 Annual Meeting
Express News | BioLine RX Ltd: New Analysis of Biopsy Samples Demonstrated a Significant Increase in Cd8+ T-Cell Density in Tumors From All 11 Patients Treated
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
BioLineRx Receives Nasdaq Minimum Bid Price Notification
Express News | BioLineRx To Present Poster On Economic Model Data For APHEXDA Today At ISPOR 2024
Buy Rating on Bioline RX Ltd for Breakthrough Stem Cell Mobilization and Enhanced Apheresis Efficiency
Express News | BioLineRx Announces Poster Presentation On Apheresis Center Efficiency And CXCR4 Antagonists Including APHEXDA At ASFA 2024 Annual Meeting Apr. 17-19
Express News | BioLineRx Has Drawn-down The Second Tranche Of $20M Under Its Previously Announced $40M Non-Dilutive Debt Financing Agreement With Funds And Accounts Managed By Blackrock
Express News | BioLineRx Shares Are Trading Lower After the Company Announced a $6 Million Registered Direct Offering
BioLineRx to Raise $6M Through a Direct Offering
No Data